Healthcare
Live Price
Offline$8.33
+13.95% today
1Y Change
+62.75%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Solid Biosciences Inc. (SLDB) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $8.33 and up 62.7% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.0%, free cash flow -56.4% with operating margin 0.0% and ROIC -89.1%. Stock Foundry combines SLDB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLDB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLDB Max Drawdown
-44.41%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLDB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.6M
+68.3% YoY
FY Net Income
-$72.2M
+16.0% YoY
Free Cash Flow
-$79.0M
+21.7% YoY
Revenue Growth
+0.0%
EPS Growth
+35.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 8M | 14M |
| Gross Profit | -2M | -2M | -3M | 8M | 14M |
| Operating Income | -179M | -130M | -104M | -106M | -72M |
| EBITDA | -178M | -122M | -93M | -97M | -69M |
| Net Income | -174M | -125M | -96M | -86M | -72M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60M | 80M | 74M | 155M | 119M |
| Total Assets | 233M | 189M | 165M | 260M | 232M |
| Total Liabilities | 53M | 51M | 38M | 49M | 24M |
| Shareholder Equity | 180M | 137M | 126M | 212M | 208M |
| Total Debt | 21M | 24M | 26M | 29M | 2M |
| Net Debt | -39M | -56M | -48M | -127M | -117M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
78M
+20.6% YoY
Capital Expenditures
1M
+57.5% YoY
Free Cash Flow
79M
+21.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.3%
Debt / Equity
0.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.